In this video, Motley Fool health care analyst Brenton Flynn takes a look at Celgene (NASDAQ:CELG) and its cancer drug Abraxane. The company's shares received a boost on Monday after releasing phase 3 data showing that the drug had a statistically significant impact on survival rates for advanced pancreatic cancer. Flynn takes us through the likelihood of Abraxane getting approval from the Food and Drug Administration, the growth potential in the market for this drug if it is approved, and what that could mean for this company's future.
